Geron Corporation (GERN)
| Market Cap | 750.58M -12.1% |
| Revenue (ttm) | 196.12M +68.6% |
| Net Income | -67.31M |
| EPS | -0.10 |
| Shares Out | 641.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,600,839 |
| Open | 1.210 |
| Previous Close | 1.210 |
| Day's Range | 1.160 - 1.210 |
| 52-Week Range | 1.040 - 2.010 |
| Beta | 0.60 |
| Analysts | Buy |
| Price Target | 3.40 (+190.6%) |
| Earnings Date | May 6, 2026 |
About GERN
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clini... [Read more]
Financial Performance
In 2025, Geron's revenue was $183.88 million, an increase of 138.83% compared to the previous year's $76.99 million. Losses were -$83.50 million, -52.17% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for GERN stock is "Buy." The 12-month stock price target is $3.4, which is an increase of 190.60% from the latest price.
News
Geron Transcript: AGM 2026
The meeting approved all board proposals, including director elections and incentive plan changes. Updates highlighted progress in clinical trials, organizational restructuring, and plans for ex-U.S. commercialization, with key trial results expected by 2028.
Geron Transcript: Stifel 2026 Targeted Oncology Virtual Forum
RYTELO's commercial rollout is accelerating, with updated NCCN guidelines supporting second-line use and strong uptake in community settings. Real-world and long-term data reinforce efficacy and safety, while financial guidance points to near-term profitability and strategic optionality.
Geron Transcript: Bank of America Global Healthcare Conference 2026
RYTELO continues to gain traction in low-risk MDS, with strong Q1 revenue and expanding use in the second-line setting. Real-world evidence supports clinical trial results, and an interim readout for imetelstat in myelofibrosis is expected later this year.
Geron to present RWE study of RYTELO at EHA Congress
Geron (GERN) Corporation announced that the first real-world evidence study of RYTELO in patients with lower-risk myelodysplastic syndromes will be presented at the European Hematology Association 202...
Geron reports Q1 EPS (1c), consensus (2c)
Reports Q1 revenue $51.84M, consensus $50.59M. “We are encouraged by RYTELO demand and net revenue growth in the first quarter. Our refocused commercial strategy, energized team, and commitment to exe...
Geron Earnings Call Transcript: Q1 2026
Q1 2026 saw 31% year-over-year revenue growth and disciplined expense management, keeping the company on track for its 2026 guidance. U.S. RYTELO demand rose 6% sequentially, with commercial and medical strategies fueling further growth and European expansion plans underway.
Geron Earnings release: Q1 2026
Geron released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Geron Quarterly report: Q1 2026
Geron has published its Q1 2026 quarterly earnings report on May 6, 2026.
Geron Slides: Corporate presentation
Geron has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Geron Transcript: 25th Annual Needham Virtual Healthcare Conference
Imetelstat, a first-in-class telomerase inhibitor, is driving growth in low-risk MDS with $184M revenue in 2025 and guidance of $220–$240M for 2026. Focus is on expanding second-line use, physician education, and advancing a pivotal myelofibrosis trial.
Geron appoints Timothy Williams as chief legal officer
Geron (GERN) announced the appointment of Timothy Williams as executive VP, chief legal officer and corporate secretary. Tim Williams served as senior VP, general counsel and Secretary at Vanda Pharma...
Geron Proxy statement: Proxy filing
Geron filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
Geron Proxy statement: Proxy filing
Geron filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
Geron Transcript: Barclays 28th Annual Global Healthcare Conference
RYTELO achieved strong initial sales and is positioned for 20–30% growth in 2026, driven by second-line MDS market expansion and a focus on community adoption. The drug's unique mechanism and positive long-term data support confidence in further uptake, while a pivotal MF trial could unlock additional value.
Geron Transcript: TD Cowen 46th Annual Health Care Conference
RYTELO achieved $184 million in first-year sales, with 2025 guidance of $220–$240 million, driven by strategic focus on second-line MDS patients and refined commercial execution. EMA approval and ongoing ISTs support international expansion and broader clinical applications.
Geron files automatic mixed securities shelf
07:50 EST Geron (GERN) files automatic mixed securities shelf
Geron Earnings Call Transcript: Q4 2025
RYTELO delivered $184M in 2025 net revenue, with strong Q4 growth and expanding prescriber base. 2026 guidance targets $220M-$240M revenue and reduced expenses, focusing on second-line, lower-risk MDS patients and continued commercial execution.
Geron Annual report: Q4 2025
Geron has published its Q4 2025 annual report on February 25, 2026.
Geron Earnings release: Q4 2025
Geron released its Q4 2025 earnings on February 25, 2026, summarizing the period's financial results.
Geron Annual report: Q4 2025
Geron has published its Q4 2025 annual report on February 25, 2026.
Geron reports Q4 EPS (5c), consensus (4c)
Reports Q4 revenue $48M, consensus $50.43M. “Strategic actions we have taken in the second half of 2025 position Geron (GERN) to drive RYTELO demand growth and invest to create value…
Geron sees FY26 Rytelo revenue $220M-$240M
For fiscal year 2026, the Company expects Rytelo net product revenue to be in the range of $220 million to $240 million. Geron (GERN) also expects total operating expenses to…
Geron Slides: Corporate presentation
Geron has posted slides in relation to its latest quarterly earnings report, which was published on February 25, 2026.
Geron price target lowered to $3 from $4 at TD Cowen
TD Cowen analyst Tara Bancroft lowered the firm’s price target on Geron (GERN) to $3 from $4 and keeps a Buy rating on the shares. The firm updated its model…
Geron sees FY26 RYTELO product revenue $220M-$240M
Sees FY26 total operating expenses expected in the range of $230 million to $240 million. “Our priorities for 2026 are clear – driving RYTELO commercial growth in the U.S., pursuing…